MLR Review for Programmatic Media: How to Get Faster Approvals
How MLR review works for programmatic media: what reviewers check in creative, targeting, and landing pages, what to submit, and how to speed approvals.
The short answer
MLR review for programmatic media checks that each asset is accurate, balanced, and on-label in the context where it will actually run: the unit size, the ISI behavior, the targeting, the placement, and the landing page. Approvals go faster when the media team submits that context up front, uses pre-approved modular content, and avoids late format changes. Most delays come from incomplete submissions, not slow reviewers.
Media teams tend to experience MLR as a black box that returns comments two weeks before launch. Reviewers tend to experience media submissions as creative files with no idea where they will run. Both sides lose time. This article explains what MLR typically looks at for programmatic, what to submit, and how to set up approvals so they move faster. Processes vary by company; follow your own SOPs.
What MLR review covers in programmatic media
MLR (medical, legal, regulatory) review is the company's internal check on promotional materials. FDA does not pre-approve most ads; companies generally submit promotional materials on Form FDA 2253 at the time of first use. That makes MLR the practical gate. Reviewers ask whether claims match the label and evidence, whether risk is presented with fair balance under 21 CFR 202.1, and whether the material meets company policy.
For programmatic, four areas usually come into scope:
| Area | What reviewers typically check | What to give them |
|---|---|---|
| Creative | Claims, visuals, ISI content and treatment, ad type, references | Every size and length, animated previews, ISI behavior notes |
| Targeting | Whether the audience is consistent with the indication; sensitive condition use; HCP versus consumer | Plain-language audience descriptions and data sources |
| Placements | Environments, adjacency, skippability, muted playback, social formats | Placement list or categories, format specs, sequencing plan |
| Landing pages | Consistency with the ad, risk near claims, links to prescribing information | URLs or staging links, plus any tag or tracking notes |
Not every company reviews targeting and placements formally. When they do not, the media team should still describe them, because a reviewer who sees "runs in 6-second bumper" will catch problems that a reviewer who sees only a storyboard will not.
What to submit so reviewers can say yes the first time
- A format matrix. Every placement, its size or length, the ad type (product claim, reminder, help-seeking), and the ISI treatment. One sheet.
- Rendered previews. Animated files or screen recordings on real devices, not only static frames.
- Audience descriptions. In plain words: "Adults 40 and over reading cardiovascular health content," not a segment ID.
- Sequencing. If a help-seeking unit and a branded unit will run to the same people, say so and show the order.
- Landing page links. With a note on which tags fire.
- What changed. For resubmissions, a clear redline of what is new versus previously approved.
This looks like extra work. It is usually less work than the second and third review rounds it prevents. The structure fits naturally into a pharma programmatic brief.
Modular approvals and pre-approved building blocks
Programmatic creates many variants: sizes, lengths, audience-specific headlines, dynamic versions. Reviewing each one from scratch is slow. Modular content approaches approve the building blocks (claims, risk statements, images, calls to action) and the rules for combining them. Variants built only from approved modules under approved rules can often move through a lighter review.
Modular approval works when the rules are concrete. "Headline A may pair with images 1 to 3, always with risk frame R1, in units 300x250 and larger" is a rule. "Use approved modules appropriately" is not. Dynamic creative depends on this; see dynamic targeting and dynamic creative in pharma. Content management platforms used in pharma (Veeva's PromoMats is a commonly named example) support this kind of workflow, but the rules still have to be written by people.
Timelines and where approvals stall
Timelines vary too much across companies to give a meaningful number. What is consistent is where time goes:
- Late format additions. A publisher needs a new size, or a 15-second cut gets added. It goes back into the queue.
- Missing context. Reviewers send questions instead of approvals.
- Unresolved ad type. The team has not decided whether a unit is reminder or help-seeking, so reviewers treat it as a product claim.
- Landing page lag. The ad is approved but the page is not, or the page changed.
- Batching. Everything submitted at once near launch, so reviewers triage.
A simple fix: book a short pre-submission meeting with the reviewer lead for any new format or tactic. Ten minutes of "here is what we plan to do and why" often saves a full cycle.
After approval: keeping what runs matched to what was approved
Approval is not the end. Trafficking should tie every live tag to an approval code and expiration. Prelaunch QA should confirm units render as approved; see the prelaunch QA checklist. Any change to creative, audience, placement type, or landing page should trigger a check against the resubmission rules. Measurement tags count too: adding a new pixel to an approved landing page can raise privacy questions even if the copy did not change.
Format specifics for ISI and video are in fair balance in digital pharma ads, and the wider regulatory map is in the pharma marketing compliance guide.
Practical takeaway
For your next submission, attach a one-page format matrix and screen recordings of every unit on a phone. Track how many review rounds it takes compared with your last submission, and share the result with your MLR lead to agree on a standard package.
Frequently asked questions
What is MLR review in pharma?
MLR stands for medical, legal, and regulatory review. It is a pharma company's internal process for checking that promotional materials are accurate, supported by evidence, consistent with the label, and compliant with FDA rules and company policy before they are used.
Does MLR review media plans or just creative?
It depends on the company, but more teams now review targeting descriptions, placements, sequencing, and landing pages alongside creative, because those affect how an ad is experienced. At minimum, reviewers need to see the formats and context each asset will run in.
How long does MLR review take?
It varies widely by company, product, and how complete the submission is. Simple changes to approved modular content can move quickly, while new claims or new formats can take several review cycles. Incomplete submissions are the most common cause of delay.
What is modular content in MLR?
Modular content means approving reusable building blocks, such as claims, risk statements, images, and calls to action, along with rules for how they can be combined. Later assets built only from approved modules under those rules can often be reviewed faster, depending on the company's process.
Sources
- FDA, The Office of Prescription Drug Promotion (OPDP)
- eCFR, 21 CFR 202.1 Prescription-drug advertisements
- FDA, Untitled Letters
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.